401 related articles for article (PubMed ID: 29054890)
21. Enhanced tumor metastasis in response to blockade of the chemokine receptor CXCR6 is overcome by NKT cell activation.
Cullen R; Germanov E; Shimaoka T; Johnston B
J Immunol; 2009 Nov; 183(9):5807-15. PubMed ID: 19812206
[TBL] [Abstract][Full Text] [Related]
22. Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand.
Petersen TR; Sika-Paotonu D; Knight DA; Dickgreber N; Farrand KJ; Ronchese F; Hermans IF
Immunol Cell Biol; 2010 Jul; 88(5):596-604. PubMed ID: 20142835
[TBL] [Abstract][Full Text] [Related]
23. Downregulation of BTLA on NKT Cells Promotes Tumor Immune Control in a Mouse Model of Mammary Carcinoma.
Sekar D; Govene L; Del Río ML; Sirait-Fischer E; Fink AF; Brüne B; Rodriguez-Barbosa JI; Weigert A
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29518903
[TBL] [Abstract][Full Text] [Related]
24. Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma.
Hunn MK; Farrand KJ; Broadley KW; Weinkove R; Ferguson P; Miller RJ; Field CS; Petersen T; McConnell MJ; Hermans IF
Clin Cancer Res; 2012 Dec; 18(23):6446-59. PubMed ID: 23147997
[TBL] [Abstract][Full Text] [Related]
25. Suppression of murine tumour growth through CD8
Kogo H; Shimizu M; Negishi Y; Uchida E; Takahashi H
Immunology; 2017 Jul; 151(3):324-339. PubMed ID: 28294313
[TBL] [Abstract][Full Text] [Related]
26. Alterations in cellular metabolism modulate CD1d-mediated NKT-cell responses.
Webb TJ; Carey GB; East JE; Sun W; Bollino DR; Kimball AS; Brutkiewicz RR
Pathog Dis; 2016 Aug; 74(6):. PubMed ID: 27297969
[TBL] [Abstract][Full Text] [Related]
27. VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells.
Tiper IV; Temkin SM; Spiegel S; Goldblum SE; Giuntoli RL; Oelke M; Schneck JP; Webb TJ
Clin Cancer Res; 2016 Aug; 22(16):4249-58. PubMed ID: 27076627
[TBL] [Abstract][Full Text] [Related]
28. Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.
Xu C; Zhang Y; Rolfe PA; Hernández VM; Guzman W; Kradjian G; Marelli B; Qin G; Qi J; Wang H; Yu H; Tighe R; Lo KM; English JM; Radvanyi L; Lan Y
Clin Cancer Res; 2017 Oct; 23(19):5869-5880. PubMed ID: 28679778
[No Abs
